SCHEMBL4128481

SCHEMBL4128481

COc1cccc2c1C(=O)NS2(=O)=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 1/20 0.57
GRK5 P34947 1/20 0.57
TYRO3 Q06418 1/20 0.57
DYRK1B Q9Y463 1/20 0.57
CA2 P00918 7/20 0.46
CA9 Q16790 7/20 0.46
CA12 O43570 6/20 0.46
CA1 P00915 5/20 0.46
CA7 P43166 4/20 0.46
KMT2A Q03164 3/20 0.46
CA4 P22748 3/20 0.46
LMNA P02545 2/20 0.46
KDM4E B2RXH2 2/20 0.46
USP2 O75604 2/20 0.46
ALPI P09923 2/20 0.46
BCHE P06276 1/20 0.46
CA6 P23280 1/20 0.46
CA5A P35218 1/20 0.46
CA14 Q9ULX7 1/20 0.46
CA5B Q9Y2D0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL645346 0.79 RET (0.53) RETGRK5TYRO3DYRK1BCA2
SCHEMBL9858525 0.78 RET (0.44) RETGRK5TYRO3DYRK1BCA2
SCHEMBL12745942 0.77 RET (0.48) RETGRK5TYRO3DYRK1BCA2
SCHEMBL7023285 0.77 RET (0.62) RETGRK5TYRO3DYRK1BCA2
SCHEMBL7278694 0.75 KDM4E (0.41) RETGRK5TYRO3DYRK1BCA2
SCHEMBL7290897 0.75 ALDH1A1 (0.46) RETGRK5TYRO3DYRK1BCA2
SCHEMBL2925304 0.75 RET (0.37) RETGRK5TYRO3DYRK1BCA2
SCHEMBL7280915 0.74 RET (0.51) RETGRK5TYRO3DYRK1BCA2
SCHEMBL10849539 0.74 RET (0.48) RETGRK5TYRO3DYRK1BCA2
SCHEMBL7280743 0.74 RET (0.59) RETGRK5TYRO3DYRK1BCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11999758-B2 Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer INVENTIVA (FR) 2024-06-04 US disclosed
EP-3860990-B1 INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER INVENTIVA (FR) 2022-09-14 EP disclosed
US-20210323982-A1 INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER INVENTIVA (FR) 2021-10-21 US disclosed
EP-3632908-A1 INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER Inventiva (FR) 2020-04-08 EP disclosed
US-20090069317-A1 Insecticidal Methods Using 3-Amino-1,2-Benzisothiazole Derivatives BASF SE (DE) 2009-03-12 US disclosed
EP-1954138-A2 INSECTICIDAL METHODS USING 3-AMINO-1,2-BENZISOTHIAZOLE DERIVATIVES BASF SE (DE) 2008-08-13 EP disclosed
US-7273861-B2 Non-nucleoside reverse transcriptase inhibitors BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2007-09-25 US disclosed
WO-2007057407-A2 INSECTICIDAL METHODS USING 3-AMINO-1,2-BENZISOTHIAZOLE DERIVATIVES BASF SE (DE) 2007-05-24 WO disclosed
US-6664251-B2 Serotonin receptor antagonist; treating cardiovascular disorder DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2003-12-16 US disclosed
US-20030078256-A1 Benzothiazine derivative SUNTORY LIMITED (JP) 2003-04-24 US disclosed
EP-0550111-A1 2-Saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and pharmaceutical compositions containing them STERLING WINTHROP INC. (US) 1993-07-07 EP disclosed
EP-0549073-A1 Novel 2-saccharinylmethyl and 4,5,6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates useful as proteolytic enzyme inhibitors and compositions and method of use thereof STERLING WINTHROP INC. (US) 1993-06-30 EP disclosed
EP-0542372-A1 2-Substituted saccharin derivative proteolytic enzyme inhibitors STERLING WINTHROP INC. (US) 1993-05-19 EP disclosed
US-5187173-A Degenerative diseases such as emphysema, rheumatoid arthritis, pancreatitis, cyctic fibrosis and skin disorders STERLING WINTHROP INC. (US) 1993-02-16 US disclosed
US-5128339-A Emphysema, rheumatoid arthritis, pancreatitis STERLING WINTHROP INC. (US) 1992-07-07 US disclosed
EP-0483928-A1 2-Saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use STERLING WINTHROP INC. (US) 1992-05-06 EP disclosed
EP-0471756-A4 SACCHARIN DERIVATIVES USEFUL AS PROTEOLYTIC ENZYME INHIBITORS AND PREPARATION THEREOF 1992-04-08 EP disclosed
EP-0471756-A1 SACCHARIN DERIVATIVES USEFUL AS PROTEOLYTIC ENZYME INHIBITORS AND PREPARATION THEREOF. STERLING WINTHROP INC (US) 1992-02-26 EP disclosed
WO-1990013549-A1 SACCHARIN DERIVATIVES USEFUL AS PROTEOLYTIC ENZYME INHIBITORS AND PREPARATION THEREOF STERLING WINTHROP INC. (US) 1990-11-15 WO disclosed
US-4404230-A ARTICIFIAL SWEETENERS DR. KARL THOMAE GMBH (DE) 1983-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069317-A1 Insecticidal Methods Using 3-Amino-1,2-Benzisothiazole Derivatives AAAS, API5, ATL3 RET 4018/4885GRK5 1421/4885TYRO3 1294/4885
US-20210323982-A1 INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER YAP1, TEAD2, YES1 RET 65/4885GRK5 1979/4885TYRO3 806/4885
US-11999758-B2 Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer YAP1, TEAD2, YES1 RET 65/4885GRK5 1979/4885TYRO3 806/4885
US-20030078256-A1 Benzothiazine derivative TPH2, ADRB2, TPH1 RET 1738/4885GRK5 269/4885TYRO3 428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.